Related Experiment Videos
Issues in polypharmacotherapy: focus on major depression
1University of Rhode Island College of Pharmacy, Providence, USA.
Psychopharmacology Bulletin
|January 1, 1996
Summary
Combination therapy, including lithium and triiodothyronine (T3), effectively treats major depressive disorders, especially treatment-resistant cases. Augmentation strategies can speed patient response to antidepressants.
Area of Science:
- Psychiatry
- Pharmacology
- Neuroscience
Background:
- Combination therapy is a common strategy in pharmacotherapy to enhance treatment efficacy.
- Polypharmacotherapy is frequently employed for major depressive disorders (MDD).
Purpose of the Study:
- To examine key issues concerning polypharmacotherapy in treating major depressive disorders.
- To discuss established and novel combination strategies for MDD.
Main Methods:
- Review of existing literature on combination pharmacotherapy for depression.
- Analysis of augmentation strategies including lithium and triiodothyronine (T3).
Main Results:
- Lithium and T3 are effective augmentation strategies for treatment-resistant depression.
- Lithium augmentation of certain antidepressants and combined serotonergic/noradrenergic agents may hasten response.
- Newer combination strategies for MDD are also considered.
Conclusions:
- Combination therapy, particularly with agents like lithium, offers significant benefits in managing major depressive disorders.
- Augmentation and combination strategies are crucial for improving treatment outcomes and response times in MDD.